Polymer compositions and methods for their use

• US 20050186244A1
• Filed: 12/02/2004
• Published: 08/25/2005
• Est. Priority Date: 11/20/2003
• Status: Abandoned Application

• Current Assignee: Angiotech Pharmaceuticals Incorporated
• Original Assignee: Angiotech Pharmaceuticals Incorporated
• Inventors: Takacs-Cox, Aniko, Hunter, William L., Toleikis, Philip M., Avelar, Rui, Gravett, David M., Loss, Troy A. E., Liggins, Richard T., Maiti, Arpita
• Application Number:
  US11/001,790
• Publication Number:
  US 20050186244A1
• Time in Patent Office: Days
• US Class Current: 424/423
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61L 2300/404 Biocides, antimicrobial agents, antiseptic agents
• CPC Class Codes: A61L 2300/416 Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
• CPC Class Codes: A61L 2300/432 Inhibitors, antagonists A61L2300/402 - A61L2300/43 take precedence
• CPC Class Codes: A61L 27/54 Biologically active materials, e.g. therapeutic substances A61L27/227 takes precedence
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 35/00 Antineoplastic agents

Abstract

Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

Claims

1-8540. -8540. (canceled)

8541. A composition comprising i) an anti-fibrotic agent and ii) a polymer or a compound that forms a polymer in situ.

8542. The composition of claim 8541 wherein the anti-fibrotic agent inhibits cell regeneration.

8543. The composition of claim 8541 wherein the anti-fibrotic agent inhibits angiogenesis.

8544. The composition of claim 8541 wherein the anti-fibrotic agent inhibits fibroblast migration.

8545. The composition of claim 8541 wherein the anti-fibrotic agent inhibits fibroblast proliferation.

8546. The composition of claim 8541 wherein the anti-fibrotic agent inhibits deposition of extracellular matrix.

8547. The composition of claim 8541 wherein the anti-fibrotic agent inhibits tissue remodeling.

8550. The composition of claim 8541 wherein the anti-fibrotic agent is a chemokine receptor antagonist.

8551. The composition of claim 8541 wherein the anti-fibrotic agent is a cell cycle inhibitor.

8552. The composition of claim 8541 wherein the anti-fibrotic agent is a taxane.

8553. The composition of claim 8541 wherein the anti-fibrotic agent is an anti-microtubule agent.

8554. The composition of claim 8541 wherein the anti-fibrotic agent is paclitaxel.

8555. The composition of claim 8541 wherein the anti-fibrotic agent is not paclitaxel.

8556. The composition of claim 8541 wherein the anti-fibrotic agent is an analogue or derivative of paclitaxel.

8557. The composition of claim 8541 wherein the anti-fibrotic agent is a vinca alkaloid.

8558. The composition of claim 8541 wherein the anti-fibrotic agent is camptothecin or an analogue or derivative thereof.

8559. The composition of claim 8541 wherein the anti-fibrotic agent is a podophyllotoxin.

8560. The composition of claim 8541 wherein the anti-fibrotic agent is a podophyllotoxin, wherein the podophyllotoxin is etoposide or an analogue or derivative thereof.

8561. The composition of claim 8541 wherein the anti-fibrotic agent is an anthracycline.

8562. The composition of claim 8541 wherein the anti-fibrotic agent is an anthracycline, wherein the anthracycline is doxorubicin or an analogue or derivative thereof.

8563. The composition of claim 8541 wherein the anti-fibrotic agent is an anthracycline, wherein the anthracycline is mitoxantrone or an analogue or derivative thereof.

8564. The composition of claim 8541 wherein the anti-fibrotic agent is a platinum compound.

8565. The composition of claim 8541 wherein the anti-fibrotic agent is a nitrosourea.

8566. The composition of claim 8541 wherein the anti-fibrotic agent is a nitroimidazole.

8567. The composition of claim 8541 wherein the anti-fibrotic agent is a folic acid antagonist.

8568. The composition of claim 8541 wherein the anti-fibrotic agent is a cytidine analogue.

8569. The composition of claim 8541 wherein the anti-fibrotic agent is a pyrimidine analogue.

8570. The composition of claim 8541 wherein the anti-fibrotic agent is a fluoropyrimidine analogue.

8571. The composition of claim 8541 wherein the anti-fibrotic agent is a purine analogue.

8572. The composition of claim 8541 wherein the anti-fibrotic agent is a nitrogen mustard or an analogue or derivative thereof.

8573. The composition of claim 8541 wherein the anti-fibrotic agent is a hydroxyurea.

8574. The composition of claim 8541 wherein the anti-fibrotic agent is a mytomicin or an analogue or derivative thereof.

8579. The composition of claim 8541 wherein the anti-fibrotic agent is a DNA alkylating agent.

8580. The composition of claim 8541 wherein the anti-fibrotic agent is an anti-microtubule agent.

8581. The composition of claim 8541 wherein the anti-fibrotic agent is a topoisomerase inhibitor.

8582. The composition of claim 8541 wherein the anti-fibrotic agent is a DNA cleaving agent.

8583. The composition of claim 8541 wherein the anti-fibrotic agent is an antimetabolite.

8584. The composition of claim 8541 wherein the anti-fibrotic agent inhibits adenosine deaminase.

8585. The composition of claim 8541 wherein the anti-fibrotic agent inhibits purine ring synthesis.

8586. The composition of claim 8541 wherein the anti-fibrotic agent is a nucleotide interconversion inhibitor.

8587. The composition of claim 8541 wherein the anti-fibrotic agent inhibits dihydrofolate reduction.

8588. The composition of claim 8541 wherein the anti-fibrotic agent blocks thymidine monophosphate.

8589. The composition of claim 8541 wherein the anti-fibrotic agent causes DNA damage.

8590. The composition of claim 8541 wherein the anti-fibrotic agent is a DNA intercalation agent.

8591. The composition of claim 8541 wherein the anti-fibrotic agent is a RNA synthesis inhibitor.

8592. The composition of claim 8541 wherein the anti-fibrotic agent is a pyrimidine synthesis inhibitor.

8593. The composition of claim 8541 wherein the anti-fibrotic agent inhibits ribonucleotide synthesis or function.

8594. The composition of claim 8541 wherein the anti-fibrotic agent inhibits thymidine monophosphate synthesis or function.

8595. The composition of claim 8541 wherein the anti-fibrotic agent inhibits DNA synthesis.

8596. The composition of claim 8541 wherein the anti-fibrotic agent causes DNA adduct formation.

8598. The composition of claim 8541 wherein the anti-fibrotic agent inhibits microtubule function.

8599. The composition of claim 8541 wherein the anti-fibrotic agent is a cyclin dependent protein kinase inhibitor.

8606. The composition of claim 8541 wherein the anti-fibrotic agent is a heat shock protein 90 antagonist.

8607. The composition of claim 8541 wherein the anti-fibrotic agent is a heat shock protein 90 antagonist, wherein the heat shock protein 90 antagonist is geldanamycin or an analogue or derivative thereof.

8609. The composition of claim 8541 wherein the anti-fibrotic agent is a HMGCoA reductase inhibitor.

8610. The composition of claim 8541 wherein the anti-fibrotic agent is a HMGCoA reductase inhibitor, wherein the HMGCoA reductase inhibitor is simvastatin or an analogue or derivative thereof.

8612. The composition of claim 8541 wherein the anti-fibrotic agent is an IKK2 inhibitor.

8613. The composition of claim 8541 wherein the anti-fibrotic agent is an IL-1 antagonist.

8614. The composition of claim 8541 wherein the anti-fibrotic agent is an ICE antagonist.

8615. The composition of claim 8541 wherein the anti-fibrotic agent is an IRAK antagonist.

8616. The composition of claim 8541 wherein the anti-fibrotic agent is an IL-4 agonist.

8617. The composition of claim 8541 wherein the anti-fibrotic agent is an immunomodulatory agent.

8618. The composition of claim 8541 wherein the anti-fibrotic agent is sirolimus or an analogue or derivative thereof.

8619. The composition of claim 8541 wherein the anti-fibrotic agent is not sirolimus.

8620. The composition of claim 8541 wherein the anti-fibrotic agent is everolimus or an analogue or derivative thereof

8621. The composition of claim 8541 wherein the anti-fibrotic agent is tacrolimus or an analogue or derivative thereof.

8622. The composition of claim 8541 wherein the anti-fibrotic agent is not tacrolimus.

8623. The composition of claim 8541 wherein the anti-fibrotic agent is biolmus or an analogue or derivative thereof.

8624. The composition of claim 8541 wherein the anti-fibrotic agent is tresperimus or an analogue or derivative thereof.

8625. The composition of claim 8541 wherein the anti-fibrotic agent is auranofin or an analogue or derivative thereof.

8626. The composition of claim 8541 wherein the anti-fibrotic agent is 27-O-demethylrapamycin or an analogue or derivative thereof.

8627. The composition of claim 8541 wherein the anti-fibrotic agent is gusperimus or an analogue or derivative thereof.

8630. The composition of claim 8541 wherein the anti-fibrotic agent is an inosine monophosphate dehydrogenase (IMPDH) inhibitor.

8631. The composition of claim 8541 wherein the anti-fibrotic agent is an IMPDH inhibitor, wherein the IMPDH inhibitor is mycophenolic acid or an analogue or derivative thereof.

8632. The composition of claim 8541 wherein the anti-fibrotic agent is an IMPDH inhibitor, wherein the IMPDH inhibitor is 1-alpha-25 dihydroxy vitamin D₃ or an analogue or derivative thereof.

8634. The composition of claim 8541 wherein the anti-fibrotic agent is a MCP-1 antagonist.

8635. The composition of claim 8541 wherein the anti-fibrotic agent is a MMP inhibitor.

8636. The composition of claim 8541 wherein the anti-fibrotic agent is an NF kappa B inhibitor.

8637. The composition of claim 8541 wherein the anti-fibrotic agent is an NF kappa B inhibitor, wherein the NF kappa B inhibitor is Bay 11-7082.

8639. The composition of claim 8541 wherein the anti-fibrotic agent is a p38 MAP kinase inhibitor.

8644. The composition of claim 8541 wherein the anti-fibrotic agent is a TNF alpha antagonist.

8645. The composition of claim 8541 wherein the anti-fibrotic agent is a TACE inhibitor.

8646. The composition of claim 8541 wherein the anti-fibrotic agent is a tyrosine kinase inhibitor.

8647. The composition of claim 8541 wherein the anti-fibrotic agent is a vitronectin inhibitor.

8648. The composition of claim 8541 wherein the anti-fibrotic agent is a fibroblast growth factor inhibitor.

8649. The composition of claim 8541 wherein the anti-fibrotic agent is a protein kinase inhibitor.

8650. The composition of claim 8541 wherein the anti-fibrotic agent is a PDGF receptor kinase inhibitor.

8651. The composition of claim 8541 wherein the anti-fibrotic agent is an endothelial growth factor receptor kinase inhibitor.

8652. The composition of claim 8541 wherein the anti-fibrotic agent is a retinoic acid receptor antagonist.

8548. (canceled)

8549. (canceled)

8575-8578. -8578. (canceled)

8600-8605. -8605. (canceled)

8608. (canceled)

8611. (canceled)

8628. (canceled)

8629. (canceled)

8633. (canceled)

8638. (canceled)

8640-8643. -8643. (canceled)

8653-8822. -8822. (canceled)

8697. The composition of claim 8541 wherein the anti-fibrotic agent inhibits protein synthesis.